首页> 外文期刊>Journal of affective disorders >Prescription patterns following first-line new generation antidepressants for depression in Japan: A naturalistic cohort study based on a large claims database
【24h】

Prescription patterns following first-line new generation antidepressants for depression in Japan: A naturalistic cohort study based on a large claims database

机译:日本针对抑郁症的一线新一代抗抑郁药的处方模式:基于大型索赔数据库的自然队列研究

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Background: Several studies have described real-world prescription patterns of first-line antidepressants for depression but little is known about their fate in terms of duration, intensity and changes. Methods: An inception cohort of new onset non-psychotic depression initiating antidepressant treatment with a new generation antidpressive agent was identified in a large health insurance claims database in Japan between 2009 and 2010. The duration and intensity of first-line antidepressants, the timing and kind of second-line antidepressants and the total duration of antidepressant treatment were examined. Results: We identified 1592 patients. The starting dose and the maximum dose attained with the firstline agent appeared to be largely in line with the guideline recommendations although the latter tended toward the minimum of the recommended range. The continuity of the first-line antidepressant was far below the guideline recommendations, with 28%never returning after the initial prescription and 55%dropping out within 3 months. Of all the first-line antidepressants, 14%were subsequently augmented by another psychotropic agent while 17%were switched to another antidepressant after a median of 3 or 2 months, respectively. The choice of the second-line agents varied extremely widely. The total duration of antidepressant therapy was as short as a median of 4 months, with 68%stopping treatment by 6 months. Limitations: The diagnosis of non-psychotic unipolar depression in the claims database analyses remains approximate. Conclusions: The current guidelines are grossly out of touch with the clinical realities. On the one hand, guidelines need to reflect the real-world practices; on the other hand clinicians should limit their treatment options and allow evidence-based comparative effectiveness research among them so that patients shall no longer be given less effective and more effective treatments without being able to distinguish among them.
机译:背景:几项研究描述了抑郁症一线抗抑郁药的现实处方模式,但就其持续时间,强度和变化而言,对其命运的了解甚少。方法:在2009年至2010年间,在日本的大型健康保险理赔数据库中确定了使用新一代抗抑郁药开始新的非精神病性抑郁症抗抑郁治疗的始发队列。一线抗抑郁药的持续时间和强度,时机和检查了二线抗抑郁药的种类以及抗抑郁药的总治疗时间。结果:我们确定了1592名患者。尽管一线药物趋向于推荐范围的最小值,但一线药物的起始剂量和最大剂量似乎与指导性建议基本一致。一线抗抑郁药的连续性远远低于指南的建议,首次处方后28%的人从不回国,而35%的人在三个月内退出。在所有一线抗抑郁药中,中位数分别为3个月或2个月后,随后有14%被另一种精神药物增强,而17%被切换为另一种抗抑郁药。二线代理商的选择差异很大。抗抑郁治疗的总时间中位数短至4个月,其中68%的治疗在6个月后停止。局限性:索赔数据库分析中对非精神病性单相抑郁症的诊断仍然是近似的。结论:当前的指南与临床现实完全脱节。一方面,准则需要反映现实世界的做法;另一方面,另一方面,临床医生应限制他们的治疗选择,并允许他们之间进行循证的比较有效性研究,以使患者不再能够在不区分治疗的情况下不再接受效果更差和更有效的治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号